Abstract
The treatment of solid malignancies includes various target drugs, such as monoclonal antibodies and tyrosine kinase inhibitors, which exert their effect alone or in combination with chemotherapy. The main part of these molecules have a target on proteins of EGFR and VEGF pathways. The particular toxicity profile and the financial impact, deriving from the application of these agents in cancer treatment, prompted a lot of researches to define predictive factors of their efficacy. Various biomarker were identified among the components of the targeted pathways. However just few studies allowed to identify specific factors to predict the toxicity of these drugs. In this review EGFR and VEGF-related pathways are described, most relevant clinical findings about target therapy applications are exposed and the clinical impact of predictive factors of efficacy and toxicity are discussed.
Keywords: VEGF, EGFR, predictive factors, toxicity, target therapy, malignancies, chemotherapy, heterodimerization, MAPK and PI3K/Akt, autophosphorylation
Current Drug Metabolism
Title: Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules
Volume: 12 Issue: 10
Author(s): Michele Caraglia, Daniele Santini, Giuseppe Bronte, Sergio Rizzo, Giovanni Sortino, Giovam Battista Rini, Gaetana Di Fede and Antonio Russo
Affiliation:
Keywords: VEGF, EGFR, predictive factors, toxicity, target therapy, malignancies, chemotherapy, heterodimerization, MAPK and PI3K/Akt, autophosphorylation
Abstract: The treatment of solid malignancies includes various target drugs, such as monoclonal antibodies and tyrosine kinase inhibitors, which exert their effect alone or in combination with chemotherapy. The main part of these molecules have a target on proteins of EGFR and VEGF pathways. The particular toxicity profile and the financial impact, deriving from the application of these agents in cancer treatment, prompted a lot of researches to define predictive factors of their efficacy. Various biomarker were identified among the components of the targeted pathways. However just few studies allowed to identify specific factors to predict the toxicity of these drugs. In this review EGFR and VEGF-related pathways are described, most relevant clinical findings about target therapy applications are exposed and the clinical impact of predictive factors of efficacy and toxicity are discussed.
Export Options
About this article
Cite this article as:
Caraglia Michele, Santini Daniele, Bronte Giuseppe, Rizzo Sergio, Sortino Giovanni, Battista Rini Giovam, Di Fede Gaetana and Russo Antonio, Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules, Current Drug Metabolism 2011; 12 (10) . https://dx.doi.org/10.2174/138920011798062346
DOI https://dx.doi.org/10.2174/138920011798062346 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytokines, Inflammation and Colon Cancer
Current Cancer Drug Targets Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets A Review on the Techniques for Characterizing and Predicting Human Genomic DNA Methylation
Current Bioinformatics Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Applied Proteomics in Companion Animal Medicine
Current Proteomics VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design (Phospho)lipid-based Nanosystems for Skin Administration
Current Pharmaceutical Design Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Ginsenoside Rh2 Improves the Cisplatin Anti-tumor Effect in Lung Adenocarcinoma A549 Cells via Superoxide and PD-L1
Anti-Cancer Agents in Medicinal Chemistry A New Role for Zn(II) Aminopeptidases: Antigenic Peptide Generation and Destruction
Current Pharmaceutical Design Estrogen Receptor Alpha: Impact of Ligands on Intracellular Shuttling and Turnover Rate in Breast Cancer Cells
Current Cancer Drug Targets Advanced Management Options for Endometriosis
Current Women`s Health Reviews Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets Research Advancements in Porcine Derived Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry New Perspective Therapy of Breast Cancer Based on Selective Dopamine Receptor D2 Agonist and Antagonist Effects on MCF-7 Cell Line
Recent Patents on Anti-Cancer Drug Discovery Epigenetic Modification Restores Functional PR Expression in Endometrial Cancer Cells
Current Pharmaceutical Design